FDA och Infant Bacterial Therapeutics överens rörande Fas III studiens utformning
May 19, 2019 14:00 ET
|
Infant Bacterial Therapeutics AB
IBT har under en längre tid rådgjort med den amerikanska läkemedelsmyndigheten FDA (US Food and Drug Administration) angående hur företagets planerade fas III studie skall utformas. FDA har nu i...
FDA and Infant Bacterial Therapeutics agree on the design of Phase III study
May 19, 2019 14:00 ET
|
Infant Bacterial Therapeutics AB
IBT has for an extended time consulted with the US Food and Drug Administration (FDA) on how the company's planned Phase III study should be designed. The FDA has now informed IBT in writing that IBT...
Årsstämma i Infant Bacterial Therapeutics
May 06, 2019 12:30 ET
|
Infant Bacterial Therapeutics AB
På årsstämman i Infant Bacterial Therapeutics AB (publ) den 6 maj 2019 beslöts bland annat följande: fastställande av årsredovisningen beviljad ansvarsfrihet för styrelseledamöter och...
Annual General Meeting of Infant Bacterial Therapeutics
May 06, 2019 12:30 ET
|
Infant Bacterial Therapeutics AB
At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 6, 2019, among other things, the following was resolved: determination of the annual reportdischarge granted to...
Infant Bacterial Therapeutics AB (publ), (IBT) Delårsrapport 1 januari – 31 mars 2019
May 06, 2019 07:00 ET
|
Infant Bacterial Therapeutics AB
VD kommenterar Som vi tidigare informerat om har IBT haft ett möte med amerikanska Food and Drug Administration (FDA) den 20 november 2018 för att diskutera IBTs kliniska utvecklingsprogram....
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – March 31, 2019
May 06, 2019 07:00 ET
|
Infant Bacterial Therapeutics AB
Message from the CEO As previously communicated, IBT had a meeting with the Food and Drug Administration (FDA) on November 20, 2018, to discuss IBT’s clinical development program. The development...
Kallelse till årsstämma i Infant Bacterial Therapeutics
April 05, 2019 11:30 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ) håller årsstämma måndagen den 6 maj 2019 kl. 15.00 i Svenska Läkaresällskapets lokaler på Klara Östra Kyrkogata 10 i Stockholm. Rätt att delta Rätt att delta i...
Notice to attend the Annual General Meeting of Infant Bacterial Therapeutics AB (publ)
April 05, 2019 11:30 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ) will hold its Annual General Meeting on Monday, May 6, 2019 at 15.00 at Svenska Läkaresällskapet på Klara Östra Kyrkogata 10 i Stockholm. Right to participate ...
Infant Bacterial Therapeutics AB sluter sitt första distributionsavtal
March 05, 2019 11:10 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB har idag gjort sitt första distributionsavtal för sin produkt IBP-9414 med Megapharm Ltd. avseende den israeliska marknaden och den palestinska myndighetens...
Infant Bacterial Therapeutics AB announces first distribution agreement
March 05, 2019 11:10 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB has today signed the first distribution agreement for IBP-9414 with Megapharm Ltd. for the Israeli market and the Palestinian Authority’s territories. The agreement...